Cell line · CVCL_0235
Papers47
1 to 20 of 47
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Inhibition of PLK1 helps to restrict c-Met-induced growth and therapeutic resistance of renal cancer cells. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| USP18 promotes clear cell renal cell carcinoma progression by regulating the ubiquitination and stability of YBX3. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Molecular Glue cc-885 Inhibits VHL-Deficient Clear Cell Renal Cell Carcinoma via ETS1 Degradation. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting and dissociating HIF2α from the molecular chaperone Hsp70 triggers apoptosis in kidney cancer. | Commun Med (Lond) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Prolonged exposure to axitinib alters the molecular profile of Caki-2 renal cell carcinoma cells. | Mol Clin Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the IL34-CSF1R axis improves metastatic renal cell carcinoma therapy outcome via immune-vascular crosstalk regulation. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| CD8+ T cell-derived CD40L mediates noncanonical cytotoxicity in CD40-expressing cancer cells. | Sci Adv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Ankrd1 Promotes Lamellipodia Formation and Cell Motility via Interaction with Talin-1 in Clear Cell Renal Cell Carcinoma. | Int J Mol Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| piRNA-1742 promotes renal cell carcinoma malignancy by regulating USP8 stability through binding to hnRNPU and thereby inhibiting MUC12 ubiquitination. | Exp Mol Med | 2023 | Its Methods give the RRID and name the line | PubMed | |
| A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma. | Mol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| GBP2 promotes clear cell renal cell carcinoma progression through immune infiltration and regulation of PD‑L1 expression via STAT1 signaling. | Oncol Rep | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Integrative Single-Cell Analysis Reveals Transcriptional and Epigenetic Regulatory Features of Clear Cell Renal Cell Carcinoma. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Transfection with Plasmid-Encoding lncRNA-SLERCC nanoparticle-mediated delivery suppressed tumor progression in renal cell carcinoma. | J Exp Clin Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Profiling of diverse tumor types establishes the broad utility of VHL-based ProTaCs and triages candidate ubiquitin ligases. | iScience | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma. | Mol Oncol | 2021 | Its Methods give the RRID and name the line | PubMed | |
| SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12. | Cell Death Dis | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Quantitative Proteomics of the Cancer Cell Line Encyclopedia. | Cell | 2020 | Cellosaurus cites it | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0235/papers